Go Pro
→ NASA's ISS Replacement Could Go to This Tiny Space Firm (From Behind the Markets) (Ad)tc pixel Free GNCAQ Stock Alerts

Genocea Biosciences (GNCAQ) Competitors

Genocea Biosciences logo
Compare

GNCAQ vs. SYRS, NAVB, GNCA, PXMD, and ARDS

Should you buy Genocea Biosciences stock or one of its competitors? Genocea Biosciences's main competitors and comparable companies include Syros Pharmaceuticals (SYRS), Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCA), PaxMedica (PXMD), and Aridis Pharmaceuticals (ARDS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Genocea Biosciences compare to Syros Pharmaceuticals?

Syros Pharmaceuticals (NASDAQ:SYRS) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Syros Pharmaceuticals Neutral
Genocea Biosciences Neutral

91.5% of Syros Pharmaceuticals shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Syros Pharmaceuticals has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, indicating that its stock price is 144% more volatile than the broader market.

Genocea Biosciences' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syros PharmaceuticalsN/A -3,369.56% -97.04%
Genocea Biosciences N/A N/A N/A

Genocea Biosciences has lower revenue, but higher earnings than Syros Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syros Pharmaceuticals$386K0.03-$164.57M-$3.03N/A
Genocea BiosciencesN/AN/AN/AN/AN/A

Summary

Syros Pharmaceuticals beats Genocea Biosciences on 4 of the 7 factors compared between the two stocks.

How does Genocea Biosciences compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Genocea Biosciences Neutral

Genocea Biosciences has lower revenue, but higher earnings than Navidea Biopharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Genocea BiosciencesN/AN/AN/AN/AN/A

Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, suggesting that its share price is 144% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Genocea Biosciences N/A N/A N/A

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Navidea Biopharmaceuticals beats Genocea Biosciences on 3 of the 5 factors compared between the two stocks.

How does Genocea Biosciences compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCAQ) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Genocea Biosciences has higher earnings, but lower revenue than Genocea Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/AN/AN/AN/A
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

Genocea Biosciences' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A N/A N/A
Genocea Biosciences N/A -182.88%-62.76%

0.6% of Genocea Biosciences shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Genocea Biosciences has a beta of 2.44, meaning that its share price is 144% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Genocea Biosciences Neutral

Summary

Genocea Biosciences beats Genocea Biosciences on 4 of the 6 factors compared between the two stocks.

How does Genocea Biosciences compare to PaxMedica?

Genocea Biosciences (NASDAQ:GNCAQ) and PaxMedica (NASDAQ:PXMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

4.9% of PaxMedica shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 1.0% of PaxMedica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
PaxMedica Neutral

Genocea Biosciences has a beta of 2.44, indicating that its share price is 144% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/AN/AN/AN/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

Genocea Biosciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A N/A N/A
PaxMedica N/A -3,167.89%-560.35%

Summary

Genocea Biosciences beats PaxMedica on 4 of the 6 factors compared between the two stocks.

How does Genocea Biosciences compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.310.00
Genocea BiosciencesN/AN/AN/AN/AN/A

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Genocea Biosciences Neutral

Aridis Pharmaceuticals has a beta of 49.95, meaning that its stock price is 4,895% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, meaning that its stock price is 144% more volatile than the broader market.

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Genocea Biosciences N/A N/A N/A

Summary

Aridis Pharmaceuticals beats Genocea Biosciences on 4 of the 4 factors compared between the two stocks.

Get Genocea Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNCAQ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNCAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

GNCAQ vs. The Competition

Export
MetricGenocea BiosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$5K$12.53B$7.26B$13.10B
Dividend YieldN/A2.63%2.52%12.57%
P/E Ratio0.00792.39274.9825.77
Price / SalesN/A850.84679.2597.61
Price / CashN/A88.6477.8052.76
Price / BookN/A10.6910.526.34
Net IncomeN/A$2.83B$3.49B$360.00M

Genocea Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNCAQ
Genocea Biosciences
N/AN/AN/AN/A$5KN/AN/A70
SYRS
Syros Pharmaceuticals
N/A$0.00
flat		N/A+300.0%$11K$386KN/A120
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
PXMD
PaxMedica
N/A$0.00
flat		N/AN/A$6KN/AN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GNCAQ) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
They're shrinking your dollars every single month
Since 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...
American Alternative | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
NASA's ISS Replacement Could Go to This Tiny Space Firm
NASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...
Behind the Markets | Sponsoredtc pixel
Analyst nicknamed “The Prophet” issues new warning for America
Whitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...
Stansberry Research | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel